Guizhou Sanli Pharmaceutical Co Ltd (603439) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.021x

Based on the latest financial reports, Guizhou Sanli Pharmaceutical Co Ltd (603439) has a cash flow conversion efficiency ratio of 0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥33.19 Million ≈ $4.86 Million USD) by net assets (CN¥1.55 Billion ≈ $226.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 603439 company net worth for the company's overall valuation and market capitalisation.

Guizhou Sanli Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Guizhou Sanli Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Guizhou Sanli Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Guizhou Sanli Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Explore how high is Guizhou Sanli Pharmaceutical Co Ltd's earnings quality to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
SG Fleet Group Ltd AU:SGF	-0.064x
MFA Financial Inc NYSE:MFA	0.073x
JOST Werke AG XETRA:JST	0.081x
Marimaca Copper Corp TO:MARI	-0.071x
Shenzhen Tellus Holding Co Ltd SHE:000025	0.009x
Asiainfo Security Technologies Corp. A SHG:688225	N/A
Jaya Real Property Tbk JK:JRPT	0.026x
Hubei Tech Semiconductors Co SHE:300046	0.008x

Annual Cash Flow Conversion Efficiency for Guizhou Sanli Pharmaceutical Co Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of Guizhou Sanli Pharmaceutical Co Ltd from 2013 to 2024. View Guizhou Sanli Pharmaceutical Co Ltd (603439) share price today for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥1.59 Billion ≈ $233.34 Million	CN¥107.07 Million ≈ $15.67 Million	0.067x	-58.52%
2023-12-31	CN¥1.71 Billion ≈ $250.13 Million	CN¥276.70 Million ≈ $40.49 Million	0.162x	-31.66%
2022-12-31	CN¥1.24 Billion ≈ $181.19 Million	CN¥293.29 Million ≈ $42.92 Million	0.237x	+57.68%
2021-12-31	CN¥1.03 Billion ≈ $151.02 Million	CN¥155.04 Million ≈ $22.69 Million	0.150x	+133.21%
2020-12-31	CN¥981.88 Million ≈ $143.68 Million	CN¥63.25 Million ≈ $9.26 Million	0.064x	-63.92%
2019-12-31	CN¥651.09 Million ≈ $95.27 Million	CN¥116.24 Million ≈ $17.01 Million	0.179x	+22.74%
2018-12-31	CN¥518.02 Million ≈ $75.80 Million	CN¥75.35 Million ≈ $11.03 Million	0.145x	+19.81%
2017-12-31	CN¥473.36 Million ≈ $69.27 Million	CN¥57.47 Million ≈ $8.41 Million	0.121x	+48.93%
2016-12-31	CN¥430.59 Million ≈ $63.01 Million	CN¥35.10 Million ≈ $5.14 Million	0.082x	-46.96%
2015-12-31	CN¥216.53 Million ≈ $31.68 Million	CN¥33.28 Million ≈ $4.87 Million	0.154x	+2870.82%
2014-12-31	CN¥108.92 Million ≈ $15.94 Million	CN¥563.46K ≈ $82.45K	0.005x	-98.81%
2013-12-31	CN¥69.09 Million ≈ $10.11 Million	CN¥30.09 Million ≈ $4.40 Million	0.435x	--

About Guizhou Sanli Pharmaceutical Co Ltd

SHG:603439 China Drug Manufacturers - Specialty & Generic

Market Cap

$865.28 Million

CN¥5.91 Billion CNY

Market Cap Rank

#9669 Global

#2506 in China

Share Price

CN¥14.46

Change (1 day)

+0.56%

52-Week Range

CN¥9.68 - CN¥17.00

All Time High

CN¥41.67